Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, Garcia V, Sempere J. Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. World J Gastroenterol 2022; 28(5): 502-516 [PMID: 35316962 DOI: 10.3748/wjg.v28.i5.502]
Corresponding Author of This Article
Jose Maria Huguet, MD, PhD, Assistant Professor, Department of Digestive Disease, General University Hospital of Valencia, Av Tres Cruces 2, Valencia 46014, Spain. josemahuguet@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Frontier
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 7, 2022; 28(5): 502-516 Published online Feb 7, 2022. doi: 10.3748/wjg.v28.i5.502
Table 1 Risk factors for the development of colorectal cancer in patients with inflammatory bowel disease and recommended surveillance
High risk
Intermediate risk
Low risk
Risk factors
(1) PSC; (2) Extensive involvement; (3) Moderate-severe active inflammation sustained over time (endoscopic or histological); (4) First-degree relative with CRC before age 50; (5) Stenosis or dysplasia detected during the previous five years; (6) Appearance of IBD at a young age; (7) If ileo-anal pouch: (a) Dysplasia; (b) Previous CRC; (c) PSC; and (d) Type C mucosa in the pouch
(1) Extensive colitis with mild or moderate sustained inflammatory activity (endoscopic or histological); (2) Inflammatory polyps; and (3) First-degree relative with CRC after age 50
(1) Factors other than high and intermediate risk; and (2) If ileo-anal pouch: Without risk factors
Surveillance
Annual
Every three years
Every five years
Table 2 SCENIC international consensus
Term
Definition
Visible dysplasia
Dysplasia identified on targeted biopsies from a lesion visualized in colonoscopy
Polypoid
Lesion protruding from the mucosa into the lumen ≥ 2.5 mm
Pedunculated
Lesion attached to the mucosa by a stalk
Sessile
Lesion not attached to the mucosa by a stalk: entire base is contiguous with the mucosa
Nonpolypoid
Lesion with little (< 2.5 mm) or no protrusion above the mucosa
Superficially elevated
Lesion with protrusion but < 2.5 mm above the lumen (less than the height of the closed cup of a biopsy forceps)
Flat
Lesion without protrusion above the mucosa
Depressed
Lesion with at least a portion depressed below the level of the mucosa
General descriptors
Ulcerated
Ulceration (fibrinous base with depth) within the lesion
Border
Distinct border
Border of the lesion is discrete and can be distinguished from surrounding mucosa
Indistinct border
Border of the lesion is not discrete and cannot be distinguished from surrounding mucosa
Invisible dysplasia
Dysplasia identified on random (non-targeted) biopsies of colon mucosa without a visible lesion
Table 3 Summary of endoscopic detection techniques
Technique
Recommendation
Future
Standard-definition colonoscopy
None
No longer used
High-definition white-light video colonoscopy and serial biopsies every 10 cm of the colon
Avoid
No longer used
High-definition white-light video colonoscopy with dye-spray chromoendoscopy (methylene blue or indigo carmine)
High
Second choice
High-definition white-light video colonoscopy with narrow-band imaging
High
First choice
Full-spectrum endoscopy
Await further evidence
Under investigation
Autofluorescence imaging
None
No longer used
Confocal laser endomicroscopy
Await further evidence
Under investigation
Endocytoscopy
Investigate
Investigate
Table 4 The Paddington International Virtual ChromoendoScopy ScOre in ulcerative colitis
PICaSSO Mucosal Architecture
PICaSSO Vascular Architecture
0 - No mucosal defect
0 - Vessels without dilatation
A: Continuous/regular crypts
A: Roundish following crypt architecture
B: Crypts not visible (scar)
B: Vessels not visible (scar)
C: Discontinuous and or dilated/elongated crypts
C: Sparse (deep) vessels without dilatation
I - Micro erosion or cryptal abscess
I - Vessels with dilatation
1: Discrete
A: Roundish with dilatation
2: Patchy
B: Crowded or tortuous superficial vessels with dilatation
3: Diffuse
II – Erosions, size < 5 mm
II - Intramucosal bleeding
1: Discrete
A: Roundish with dilatation
2: Patchy
B: Crowded or tortuous superficial vessels with dilatation
3: Diffuse
III – Ulcerations, size > 5 mm
III - Luminal bleeding
1: Discrete
A: Roundish with dilatation
2: Patchy
B: Crowded or tortuous superficial vessels with dilatation
3: Diffuse
Citation: Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, Garcia V, Sempere J. Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. World J Gastroenterol 2022; 28(5): 502-516